Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.